YMAB: Y-Mabs Therapeutics Inc Company Profile & Statistics

About

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Info & Links

CEO

Michael Rossi

Headquarters

230 Park Avenue Suite 3350
NEW YORK, NY 10169, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

100

Y-Mabs Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

420.58M

Enterprise Value

352.46M

Enterprise Value/EBITDA(ttm)

-12.65

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

5.00

Price to Book(mrq)

4.55

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

88.84%

Operating Margin(ttm)

-28.22%

Profit Margin(ttm)

-28.99%

Return on Equity(ttm)

-24.61%

Return on Invested Capital(ttm)

-24.93%

Return on Assets(ttm)

-18.49%

Income Statement

Revenue(ttm)

84.55M

Revenue Per Share(ttm)

1.89

Gross Profit(ttm)

75.16M

EBITDA(ttm)³

-27.87M

Net Income Available to Common(ttm)

-23.86M

Diluted EPS(ttm)

-0.54

Share Statistics

Beta (5Y Monthly)

0.61

52-Week Change

48.58%

S&P 500 52-Week Change

27.84%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

44.79M

Dividend Yield

0.00%

Float⁴

34.71M

% Held by Insiders

22.50%

% Held by Institutions

70.85%

Balance Sheet

Total Cash(mrq)

68.12M

Total Cash Per Share(mrq)

1.52

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.92%

Quick Ratio(mrq)

3.54%

Book Value Per Share(mrq)

2.06

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.31

Free Cash Flow(ytd)

-13.84M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

YMAB

Y-Mabs Therapeutics Inc

Y-Mabs Therapeutics Inc Profile